Advertisement

Repair of CFTR Folding Defects with Correctors that Function as Pharmacological Chaperones

  • Tip W. Loo
  • David M. ClarkeEmail author
Protocol
Part of the Methods in Molecular Biology book series (MIMB, volume 741)

Abstract

The major cause of cystic fibrosis is the presence of processing mutations in CFTR (such as deletion of Phe-508 (F508del-CFTR)) that disrupt folding of the protein and trafficking to the cell surface. Processing mutations appear to inhibit folding of CFTR so that it accumulates in the endoplasmic reticulum as a partially folded protein. Expressing the proteins in the presence of small molecules called correctors can repair CFTR folding defects. Some correctors appear to function as pharmacological chaperones that specifically bind to the CFTR processing mutants and induce them to complete the folding process. In this chapter, we describe techniques to examine the effects of correctors on folding of CFTR processing mutants.

Key words

F508del-CFTR corrector processing mutant protein folding glycosylation disulfide cross-linking protein maturation 

Notes

Acknowledgments

This work was supported by funds from the Canadian Institutes for Health Research (Grant 62832) and the Cystic Fibrosis Foundation (Grant CLARKE08GO).

References

  1. 1.
    Riordan, J. R., Rommens, J. M., Kerem, B., Alon, N., Rozmahel, R., Grzelczak, Z. et al. (1989) Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 245, 1066–1073.PubMedCrossRefGoogle Scholar
  2. 2.
    Welsh, M. J., and Smith, A. E. (1993) Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis. Cell 73, 1251–1254.PubMedCrossRefGoogle Scholar
  3. 3.
    Loo, T. W., and Clarke, D. M. (1997) Correction of defective protein kinesis of human P-glycoprotein mutants by substrates and modulators. J. Biol. Chem. 272, 709–712.PubMedCrossRefGoogle Scholar
  4. 4.
    Loo, T. W., Bartlett, M. C., and Clarke, D. M. (2005) Rescue of ΔF508 and other misprocessed CFTR mutants by a novel quinazoline compound. Mol. Pharm. 2, 407–413.PubMedCrossRefGoogle Scholar
  5. 5.
    Van Goor, F., Straley, K. S., Cao, D., Gonzalez, J., Hadida, S., Hazlewood, A., et al. (2006) Rescue of ΔF508 CFTR trafficking and gating in human cystic fibrosis airway primary cultures by small molecules. Am. J. Physiol. Lung Cell Mol. Physiol. 290, L1117–L1130.PubMedCrossRefGoogle Scholar
  6. 6.
    Pedemonte, N., Lukacs, G. L., Du, K., Caci, E., Zegarra-Moran, O., Galietta, L. J., et al. (2005) Small-molecule correctors of defective DeltaF508-CFTR cellular processing identified by high-throughput screening. J. Clin. Invest. 115, 2564–2571.PubMedCrossRefGoogle Scholar
  7. 7.
    Carlile, G. W., Robert, R., Zhang, D., Teske, K. A., Luo, Y., Hanrahan, J. W. et al. (2007) Correctors of protein trafficking defects identified by a novel high-throughput screening assay. Chembiochem 8, 1012–1020.PubMedCrossRefGoogle Scholar
  8. 8.
    Loo, T. W., and Clarke, D. M. (2005) Rescue of folding defects in ABC transporters using pharmacological chaperones. J. Bioenerg. Biomembr. 37, 501–507.PubMedCrossRefGoogle Scholar
  9. 9.
    Chen, E. Y., Bartlett, M. C., and Clarke, D. M. (2000) Cystic fibrosis transmembrane conductance regulator has an altered structure when its maturation is inhibited. Biochemistry 39, 3797–3803.PubMedCrossRefGoogle Scholar
  10. 10.
    Du, K., Sharma, M., and Lukacs, G. L. (2005) The ΔF508 cystic fibrosis mutation impairs domain-domain interactions and arrests post-translational folding of CFTR. Nat. Struct. Mol. Biol. 12, 17–25.PubMedCrossRefGoogle Scholar
  11. 11.
    Loo, T. W., Bartlett, M. C., and Clarke, D. M. (2009) Correctors enhance maturation of DeltaF508 CFTR by promoting interactions between the two halves of the molecule. Biochemistry 48, 9882–9890.PubMedCrossRefGoogle Scholar
  12. 12.
    Chen, E. Y., Bartlett, M. C., Loo, T. W., and Clarke, D. M. (2004) The ΔF508 mutation disrupts packing of the transmembrane segments of the cystic fibrosis transmembrane conductance regulator. J. Biol. Chem. 279, 39620–39627.PubMedCrossRefGoogle Scholar
  13. 13.
    Chen, C., and Okayama, H. (1987) High-efficiency transformation of mammalian cells by plasmid DNA. Mol. Cell Biol. 7, 2745–2752.PubMedGoogle Scholar
  14. 14.
    Loo, T. W., and Clarke, D. M. (1994) Reconstitution of drug-stimulated ATPase activity following co-expression of each half of human P-glycoprotein as separate polypeptides. J. Biol. Chem. 269, 7750–7755.PubMedGoogle Scholar
  15. 15.
    Loo, T. W., Bartlett, M. C., and Clarke, D. M. (2008) Correctors promote folding of the CFTR in the endoplasmic reticulum. Biochem. J. 413, 29–36.PubMedCrossRefGoogle Scholar
  16. 16.
    Mense, M., Vergani, P., White, D. M., Altberg, G., Nairn, A. C., and Gadsby, D. C. (2006) In vivo phosphorylation of CFTR promotes formation of a nucleotide-binding domain heterodimer. EMBO. J. 25, 4728–4739.PubMedCrossRefGoogle Scholar
  17. 17.
    Wang, Y., Loo, T. W., Bartlett, M. C., and Clarke, D. M. (2007) Correctors promote maturation of cystic fibrosis transmembrane conductance regulator (CFTR)-processing mutants by binding to the protein. J. Biol. Chem. 282, 33247–33251.PubMedCrossRefGoogle Scholar
  18. 18.
    Loo, T. W., Bartlett, M. C., and Clarke, D. M. (2008) Processing mutations disrupt interactions between the nucleotide binding and transmembrane domains of P-glycoprotein and the cystic fibrosis transmembrane conductance regulator (CFTR). J. Biol. Chem. 283, 28190–28197.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  1. 1.Departments of Medicine and BiochemistryUniversity of TorontoTorontoCanada

Personalised recommendations